CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer

Inclusion Criteria

• •Documented informed consent of the participant and/or legally authorized representative
• •* Assent, when appropriate, will be obtained per institutional guidelines
• •Agreement to research biopsies on study, once during study and end of study, exceptions may be granted with study principal investigator (PI) approval
• •\>= 18 years
• •Eastern Cooperative Oncology Group (ECOG) =\< 2
• •Histologically confirmed metastatic triple negative breast cancer. Triple negative status will be defined as estrogen receptor (ER) and progesterone receptor (PR) =\< 10% by immunohistochemistry (IHC) and HER2 negative, per American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines
• •Measurable disease by RECIST 1.1
• •Patients must have progressed on or been intolerant of at least 2 prior lines of therapy for advanced/metastatic disease. Patients that qualify for immunotherapy and/or PARP inhibitors must have progressed on or been intolerant of these agents
• •Fully recovered from the acute toxic effects (except alopecia) to =\< grade 2 to prior anti-cancer therapy
• •Must have a superficial tumor (cutaneous, subcutaneous), breast lesion or nodal metastases amenable to safe repeated intratumoral injections per treating physician and interventional radiologist review
• •Absolute neutrophil count (ANC) \>= 1,500/mm\^3
• •* NOTE: Growth factor is not permitted within 14 days of ANC assessment unless cytopenia is secondary to disease involvement
• •Platelets \>= 100,000/mm\^3
• •* NOTE: Platelet transfusions are not permitted within 14 days of platelet assessment unless cytopenia is secondary to disease involvement
• •Total bilirubin =\< 1.5 X upper limit of normal (ULN)
• •Aspartate aminotransferase (AST) =\< 2.5 x ULN
• •* If liver metastases are present: AST =\< 5 x ULN
• •Alanine aminotransferase (ALT) =\< 2.5 x ULN
• •* If liver metastases are present: ALT =\< 5 x ULN
• •Serum creatinine =\< 1.5 mg/dL or creatinine clearance of \>= 50 mL/min per 24 hour urine test or the Cockcroft-Gault formula
• •Prothrombin (PT) =\< 1.5 x ULN
• •Activated partial thromboplastin time (aPTT) =\< 1.5 x ULN
• •Women of childbearing potential (WOCBP): negative serum pregnancy test
• •Agreement by females and males of childbearing potential\* and their partners to use an effective method of birth control (defined as a hormonal or barrier method) or abstain from heterosexual activity for the course of the study through at least 6 months after the last dose of protocol therapy
• •* Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for \> 1 year (women only)